Despite these limitations, to the best of our knowledge, this is the first study to show the benefits of ICI plus chemotherapy in terms of PFS in patients with NSCLC who present with rare oncogenic driver mutations other than EGFR mutations and ALK fusion. The gene discussed is ALK; the disease is non-small cell lung carcinoma.